C
CAGE BIO INC.
CAGE Bio, Inc. envisions to transform ionic liquids into health care solutions.
Country/Area ：United States
Company Email ：admin@cagebio.com
Industry ：BiotechnologyBusiness ServicesBusiness Services General
Company address ：733 Industrial Rd, San Carlos, California, 94070, United States
Company website ：*****
Company phone ：(501) 229-9458
Established ：2018
Company Revenue ：$991,000
Number of employees ：0 - 9
SIC Code ：87873
NAICS Code ：54541
Main Products ：PublicationsScientific Advisory BoardPartnershipsBusiness AdvisorsClinical TrialsBoard of Directors
Company News
CAGE Bio, TAGCyx, and PeptiStar Announce Execution of a License Agreement for Development and Commercialization of TAGX-0003 for the Treatment of Immunodermatology Diseases Mediated by the IFN-Gamma Pathway
Sep 15, 2022
CAGE Bio Inc. (hereinafter "CAGE Bio"), a biotechnology company focused on developing innovative therapies for infection, inflammation and immunology and TAGCyx Biotechnologies Inc. (hereinafter "TAGCyx"), a biotechnology company developing DNA aptamer drugs based on its proprietary artificial nucleic acid base pair technology, announce the execution of a license agreement for development of TAGX-0003 for the targeted treatment of alopecia areata
Sep 15, 2022
CAGE Bio Initiates Phase 2 Study for Treatment of RosaceaMay 11, 2021
SAN CARLOS, Calif., May 11, 2021 /PRNewswire/ -- CAGE Bio Inc., a biotechnology company focused on developing innovative therapies for infection, inflammation and immunology, announced dosing of the first patient in its Phase 2 clinical trial for the treatment of inflammatory lesions of...
May 11, 2021CAGE Bio Closes $7.2 Million Round of Series A FundingFeb 16, 2021
/PRNewswire/ -- CAGE Bio Inc., an innovative biotechnology company focused on developing innovative therapies for infection, inflammation and immunology,...
Feb 16, 2021Biotech Startup Announces R&D Collaboration With Major Japanese Drug Delivery CompanyJul 7, 2020
SAN CARLOS, Calif., July 7, 2020 /PRNewswire/ -- CAGE Bio Inc. today announced a research and development agreement with Nitto Denko Corporation for a transdermal formulation of undisclosed molecules. The goal of the partnership is to explore the potential for developing therapeutic...
Jul 7, 2020Web Summary
Q1: What is the physical address of CAGE Bio Inc., and how can one get in touch with them?
A1: The physical address of CAGE Bio Inc. is 733 Industrial Road, San Carlos, CA 94070, and one can contact them through phone at +1 (501) 229-9458 or email at admin@cagebio.com.
Q2: What is the mission statement of CAGE Bio Inc., and how does it relate to their products and services?
A2: The mission statement of CAGE Bio Inc. is to develop localized treatment options that match the efficacy of systemic drugs with the safety of local, topical administration. This aligns with their focus on creating ionic liquid formulations for various skin health conditions.
Q3: Who are some key members of CAGE Bio's product development team, and what are their backgrounds?
A3: Some key members of CAGE Bio's product development team include Marina Shevachman (Sr. Director, Product Development), Chase Corley (M.S. Scientist II, Product Development), Jason Mars (M.S. Scientist I, Product Development), Elaine Campbell (Sr. Scientist, Product Development), and Drew Sturtevant (Scientist III, Product Development). They bring a range of expertise in drug development, commercial manufacturing, and molecular biology.
Q4: What is the company's approach to quality and regulatory oversight, as represented by Patricia Oto Rph?
A4: Patricia Oto Rph serves as the Quality and Regulatory Lead at CAGE Bio Inc., bringing over 25 years of executive leadership experience with regulatory and quality oversight. She has worked on global regulatory submissions in several therapeutic areas.
Q5: What is the company's focus on clinical trials, particularly in relation to their product pipeline?
A5: CAGE Bio Inc. is involved in various clinical trials, including a double-blind Phase 2 study evaluating an ionic liquid formulation of 1% Tofacitinib for patients with atopic dermatitis. They aim to develop localized treatment options that match the efficacy of systemic drugs.
Q6: How does Shashwati Godbole contribute to CAGE Bio Inc., and what is her background?
A6: Shashwati Godbole joins CAGE Bio Inc. as a Program Manager, bringing research and industry experience within the Medical Affairs Operations and Management space. She received her M.S. in Biotechnology from Northeastern University.
Q7: What is the company's stance on skin health, as reflected in their mission statement?
A7: CAGE Bio Inc.'s mission is to revolutionize skin health by developing localized treatment options that match the efficacy of systemic drugs with the safety of local, topical administration. They aim to improve patient outcomes and quality of life for individuals with various skin conditions.
Q8: What are some notable achievements or milestones in CAGE Bio Inc.'s history, as represented by their news section?
A8: The company has recently announced positive top-line results from a double-blind Phase 2 study evaluating an ionic liquid formulation of 1% Tofacitinib for patients with atopic dermatitis. This achievement highlights the company's commitment to developing innovative treatments for skin health conditions.
A1: The physical address of CAGE Bio Inc. is 733 Industrial Road, San Carlos, CA 94070, and one can contact them through phone at +1 (501) 229-9458 or email at admin@cagebio.com.
Q2: What is the mission statement of CAGE Bio Inc., and how does it relate to their products and services?
A2: The mission statement of CAGE Bio Inc. is to develop localized treatment options that match the efficacy of systemic drugs with the safety of local, topical administration. This aligns with their focus on creating ionic liquid formulations for various skin health conditions.
Q3: Who are some key members of CAGE Bio's product development team, and what are their backgrounds?
A3: Some key members of CAGE Bio's product development team include Marina Shevachman (Sr. Director, Product Development), Chase Corley (M.S. Scientist II, Product Development), Jason Mars (M.S. Scientist I, Product Development), Elaine Campbell (Sr. Scientist, Product Development), and Drew Sturtevant (Scientist III, Product Development). They bring a range of expertise in drug development, commercial manufacturing, and molecular biology.
Q4: What is the company's approach to quality and regulatory oversight, as represented by Patricia Oto Rph?
A4: Patricia Oto Rph serves as the Quality and Regulatory Lead at CAGE Bio Inc., bringing over 25 years of executive leadership experience with regulatory and quality oversight. She has worked on global regulatory submissions in several therapeutic areas.
Q5: What is the company's focus on clinical trials, particularly in relation to their product pipeline?
A5: CAGE Bio Inc. is involved in various clinical trials, including a double-blind Phase 2 study evaluating an ionic liquid formulation of 1% Tofacitinib for patients with atopic dermatitis. They aim to develop localized treatment options that match the efficacy of systemic drugs.
Q6: How does Shashwati Godbole contribute to CAGE Bio Inc., and what is her background?
A6: Shashwati Godbole joins CAGE Bio Inc. as a Program Manager, bringing research and industry experience within the Medical Affairs Operations and Management space. She received her M.S. in Biotechnology from Northeastern University.
Q7: What is the company's stance on skin health, as reflected in their mission statement?
A7: CAGE Bio Inc.'s mission is to revolutionize skin health by developing localized treatment options that match the efficacy of systemic drugs with the safety of local, topical administration. They aim to improve patient outcomes and quality of life for individuals with various skin conditions.
Q8: What are some notable achievements or milestones in CAGE Bio Inc.'s history, as represented by their news section?
A8: The company has recently announced positive top-line results from a double-blind Phase 2 study evaluating an ionic liquid formulation of 1% Tofacitinib for patients with atopic dermatitis. This achievement highlights the company's commitment to developing innovative treatments for skin health conditions.
Customs Data
As a purchaser
As a Supplier
Get the Whole details
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Get the Whole details
